Table 3 Cox regression for overall and disease-free survival using only tumor type and ASCO–CAP 2018 ISH Groups.

From: Clinical significance of quantitative categorization of HER2 fluorescent in situ hybridization results in invasive breast cancer patients treated with HER2-targeted agents

Prognostic variable

Hazard ratio

Lower .95

Upper .95

p value

Overall survival

 Tumor type

2.180

1.345

3.532

0.0015

 ASCO–CAP ISH Groups

1.296

1.111

1.513

0.0010

Disease-free survival

 Tumor type

1.837

1.111

3.040

0.0178

 ASCO–CAP ISH Groups

1.325

1.136

1.546

0.0003

  1. ASCO–CAP American Society of Clinical Oncology–College of American Pathologist, ISH in situ hybridization.
Back to article page